A Phase II Study of Triple-negative Breast Cancer Brain Metastases.

This study is testing whether a combination of a chemotherapy drug and an immunotherapy drug can treat triple-negative breast cancer (TNBC) that has spread to the brain — a type of cancer with very few treatment options. **You may be eligible if...** - You are between 18 and 70 years old - You have been diagnosed with triple-negative breast cancer (hormone receptor-negative and HER2-negative) - Your cancer has spread or come back and cannot be removed with surgery or treated with radiation - You have brain metastases (cancer that has spread to the brain) - You are in reasonably good health (ECOG performance status 0-2) - You have not previously used platinum-based chemotherapy, or if you have, your cancer responded to it for at least 3 months **You may NOT be eligible if...** - You have HER2-positive or hormone receptor-positive breast cancer - Your cancer did not respond to prior platinum-based chemotherapy - You are pregnant or breastfeeding - Your organ function does not meet minimum requirements Talk to your doctor to see if this trial is right for you.